At the most recent ASDS meeting, Catherine DiGiorgio, M.D., Boston, discusses the current state of noninvasive body contouring, and what noninvasive devices and procedures will soon hit the market including a collagenase clostridium histolyticum injection and cellulite-targeting devices that use electromagnetic stimulation and radiofrequency.
LEO Pharma announces azelaic acid foam 15% (Finacea) is now available on the market to treat inflammatory papules and pustules of mild-to-moderate rosacea.
LEO Pharma has entered into a license agreement with Oneness Biotech and Microbio Shanghai for the development and commercialization of the investigational drug FB825 for the treatment of atopic dermatitis and asthma.
This week’s edition of The Mainstream Patient revolves around COVID-19, featuring articles about the effects of blue light on our skin, wearing sunscreen even while indoors, the integration of teledermatology and how the pandemic is affecting front line workers' skin.
Eli Lilly announces the U.S. Food and Drug Administration approval of ixekizumab (Taltz) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6 and under 18 who are also eligible for phototherapy and systemic therapy.
Introducing The Mainstream Patient, a weekly glimpse into what your patients may be reading in the media about skin health.
HEINE, a global primary diagnostic instrument manufacturer, announces two new dermatoscopes available for purchase in the U.S.
REVIAN Inc. releases data from their investigational study examining their REVIAN RED dual wavelength LED light treatment for androgenetic alopecia, showing the FDA-cleared device to be both safe and effective at week 16 in a 26-week trial.
Introducing The Mainstream Patient, a weekly glimpse into what your patients may be reading in the media about skin health.
The American Medical Association announces new resources for private practice physicians during the COVID-19 pandemic.
Pfizer announces top-line results from its third phase 3 clinical trial investigating abrocitinib in adults with moderate-to-severe atopic dermatitis.
Introducing The Mainstream Patient, a weekly glimpse into what your patients may be reading in the media about skin health.
Gladskin announces the launch of its over-the-counter eczema topical in the U.S, which features the company’s patented Micreobalance technology.
The Journal of Drugs in Dermatology is making additional resources available to medical professionals who wish to continue their education in light of medical conference cancelations due to COVID-19.
Galderma has announced a plan to expand their aesthetic portfolio by enhancing their ASPIRE Galderma Rewards mobile app, investing in their salesforce and collaborating with a skin care company.
Introducing The Mainstream Patient, a weekly glimpse into what your patients may be reading in the media about skin health.
Soliton has received 510(k) clearance from the U.S. FDA for its Generation II Rapid Acoustic Pulse (RAP) device for tattoo removal.
Introducing The Mainstream Patient, a weekly glimpse into what your patients may be reading in the media about skin health.
The Dermatology Innovation Forum has announced its cancellation amid global spread of the coronavirus.
The American Academy of Dermatology Board of Directors has decided to cancel the 2020 Annual Meeting in Denver due to coronavirus concerns.
Sun Dermatology is launching an acne awareness advertising campaign, Take on Acne, that focuses on the skin condition’s impact on teens and young adults’ quality of life.
Introducing The Mainstream Patient, a weekly glimpse into what your patients may be reading in the media about skin health.
Positive phase 3 results from two clinical trials suggests that Sol-Gel’s novel 5% microencapsulated benzoyl peroxide cream may offer quick, effective relief for patients with papulopustular rosacea.
Sun Pharma introduces a lower dose isotretinoin capsule in the U.S. for the treatment of severe recalcitrant nodular acne.
A combination of ivermectin 1% cream and oral 40-mg doxycycline has the potential to be an effective therapy for some people with moderate to severe rosacea after the publication of results from a phase 3b/4 study examining the combination’s efficacy and safety compared to ivermectin as a monotherapy.
Eli Lilly and Incyte announces positive results of two phase 3 clinical trials investigating the use of JAK inhibitor baricitinib as both a monotherapy and combination therapy for moderate-to-severe atopic dermatitis.
